Melflufen (INN melphalan flufenamide) was granted priority review from FDA in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD-38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients). The FDA has set a PDUFA-date (Prescription Drug User Fee Act), which is the target date for their review of the New Drug Application, to February 28, 2021.
In this episode of The Cancer Letter Podcast, Jacquelyn and Paul talk about the first meeting of the National Cancer Advisory Board, the uncertainty of cancer registries, and about choosing what to cover as the Trump administration “floods the zone.”
